<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in patients with HIV</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in patients with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in patients with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christine Johnston, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna Wald, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 21, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H6231103"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Herpes simplex virus type 2 (HSV-2) is the leading cause of genital ulcer disease (GUD) worldwide [<a href="#rid1">1-5</a>]. Persons with HIV have a higher prevalence of HSV-2 infection, an increased risk of asymptomatic HSV genital shedding, and may have unusual clinical manifestations of HSV-2-related disease compared with HSV-2-seropositive patients who are HIV-uninfected. </p><p>This topic will review the epidemiology, clinical manifestations and diagnosis of HSV-2 infection in the HIV-infected host. The treatment of genital HSV in the host with HIV and the viral interactions between HIV and HSV-2 are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/16255.html" rel="external">"Treatment of genital herpes simplex virus type 2 in people living with HIV"</a> and  <a class="medical medical_review" href="/d/html/16701.html" rel="external">"Treatment of drug-resistant genital herpes simplex virus infection in patients with HIV"</a>.)</p><p class="headingAnchor" id="H970262"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The clinical designations of genital HSV infection are: primary, nonprimary first episode, and recurrent or reactivation disease  (<a class="graphic graphic_table graphicRef80693" href="/d/graphic/80693.html" rel="external">table 1</a>). Among patients presenting with first episode of genital herpes, both virologic and serologic information is needed to accurately define the category of infection. </p><p class="headingAnchor" id="H970224"><span class="h2">Primary</span><span class="headingEndMark"> — </span>Primary infection refers to HSV infection in a patient without pre-existing antibodies to either HSV-1 or HSV-2. </p><p class="headingAnchor" id="H970231"><span class="h2">Nonprimary</span><span class="headingEndMark"> — </span>Nonprimary first-episode infection typically refers to the acquisition of genital HSV-2 in a patient with preexisting antibodies to HSV-1. The converse is rare because HSV-2 infection is thought to provide protection against genital HSV-1 infection. Most adults with HIV and a first episode of HSV-2 infection have nonprimary infection because of prior infection with HSV-1 [<a href="#rid6">6,7</a>]. </p><p class="headingAnchor" id="H970361"><span class="h2">Reactivation disease</span><span class="headingEndMark"> — </span>Antiviral treatment during newly acquired infection lessens morbidity, but does not eradicate latent virus, which can subsequently reactivate in immunocompetent or immunocompromised hosts. Patients with a new diagnosis of HSV-2 infection should be counseled to expect recurrence of genital ulcers. </p><p class="headingAnchor" id="H2392163"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>There is a strong association between HSV-2 and HIV prevalence [<a href="#rid8">8</a>]. Epidemiologic studies demonstrate that HSV-2 seroprevalence is disproportionately higher among persons with compared to those without HIV with comparable demographic and behavioral risk factors for HSV-2 acquisition [<a href="#rid8">8-16</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a surveillance study of 3280 Peruvian men who have sex with men (MSM), a significantly greater proportion of males with HIV were coinfected with HSV-2 compared with males without HIV (81 versus 41 percent) [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort of 700 persons with HIV in the United States, 60 percent were HSV-2-seropositive, which is threefold higher than among the general United States population [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 38,691 adults participating in HIV Prevention Trials Network 071 (PopART study), the odds of HIV infection were &gt;6-fold higher in both males and females with HSV-2 infection [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H2392466"><span class="h1">NATURAL HISTORY</span></p><p class="headingAnchor" id="H744885"><span class="h2">Clinical disease</span><span class="headingEndMark"> — </span>The natural history of HSV-2 infection is altered among patients with HIV infection [<a href="#rid18">18</a>]. Among HSV-2 seropositive patients, concomitant HIV infection is associated with [<a href="#rid19">19-23</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Increased frequency and severity of HSV-2 reactivation disease </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical clinical manifestations of HSV-2 reactivation episodes </p><p></p><p>Among immunocompetent hosts, an average of four recurrences will occur during the first year after acquisition; recurrent genital lesions generally resolve within a median of four days with antiviral therapy [<a href="#rid24">24</a>]. In comparison with HIV-seronegative persons, genital HSV-2 recurrences in patients with HIV are more frequent and the episodes are of longer duration [<a href="#rid25">25-28</a>].</p><p>Persistent, non-healing lesions caused by HSV-2 are more common in patients with advanced immunosuppression (eg, CD4 cell counts less than 100 cells/mm<sup>3</sup>) [<a href="#rid19">19,26</a>], supporting the importance of cell-mediated immunity in controlling genital herpes. In addition, severe genital ulcers are associated with impaired HSV-specific CD8+ cytotoxic T-cell responses in persons with HIV [<a href="#rid29">29</a>]. (See <a class="local">'Ulcerative disease'</a> below.)</p><p class="headingAnchor" id="H744892"><span class="h2">Viral shedding</span><span class="headingEndMark"> — </span>HSV-2 is detected frequently from mucosal genital surfaces in the absence of genital ulcerative disease, referred to as “subclinical shedding” [<a href="#rid30">30,31</a>]. HSV-2 shedding is more frequent among males and females with HIV compared with those without HIV [<a href="#rid21">21,27,32</a>]. Among persons with HIV, the risk of HSV-2 shedding, as measured by polymerase chain reaction (PCR), is approximately six-fold greater in those with CD4 cell counts &lt;200 cells/microL [<a href="#rid33">33</a>]. Increased rates of HSV-2 detection in the genital tract (using culture-based methods), are also associated with higher plasma HIV-1 RNA levels [<a href="#rid34">34</a>]. </p><p class="headingAnchor" id="H13152652"><span class="h2">Effect of antiretroviral therapy on HSV-2-related disease</span><span class="headingEndMark"> — </span>Small observational studies report conflicting results as to whether antiretroviral therapy (ART) ameliorates HSV-related ulcers and viral shedding among patients with HIV and immunosuppression [<a href="#rid9">9,35,36</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>In an observational study of 77 persons with HIV and recurrent disease, ART was associated with fewer days with genital ulceration (3 percent versus 11 percent of days); however, no significant change in the frequency or quantity of HSV-2 shedding was seen [<a href="#rid35">35</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Women’s Interagency HIV Study (WIHS), the frequency of genital ulcers did not change with the initiation of ART; genital HSV-2 shedding was not measured [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H11525287"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>As noted above, patients with HIV usually presents with HSV-related reactivation disease; the clinical manifestations are influenced by the patient’s current and prior immunologic status, as evidenced by CD4 cell counts [<a href="#rid20">20,23</a>]. (See <a class="local">'Definitions'</a> above.)</p><p class="headingAnchor" id="H6231117"><span class="h2">Ulcerative disease</span><span class="headingEndMark"> — </span>In patients with well-controlled HIV disease, HSV-2-related genital ulcerations may range from painless ulcers [<a href="#rid27">27,31,37</a>] to typical shallow, erosive genital lesions approximately 2 to 7 millimeters in size. Symptoms of genital ulcers can include pain, tingling, and pruritus. Patients with ulcers near the urethra may complain of external dysuria. Others may have only subclinical shedding of virus without any mucocutaneous lesions, even during a careful examination [<a href="#rid25">25</a>].</p><p>However, in patients with AIDS, deep genital or perianal ulcerations or fissures have been described, which can be quite painful [<a href="#rid27">27,28,38</a>]. In the era prior to ART, chronic expanding ulcerative perianal lesions associated with HSV-2 infection were commonly observed among patients with severe immunosuppression (eg, CD4 counts &lt;50 cells/mm<sup>3</sup>) [<a href="#rid19">19,39</a>]. Of note, persistent mucocutaneous HSV-2-related ulcers lasting greater than one month were among the first opportunistic infections to be classified as an AIDS-defining event  (<a class="graphic graphic_picture graphicRef81569" href="/d/graphic/81569.html" rel="external">picture 1</a>) [<a href="#rid28">28,38,40</a>]. These patients often had fever and weight loss related to other concomitant opportunistic infections [<a href="#rid38">38</a>]. </p><p class="headingAnchor" id="H6231124"><span class="h2">Hypertrophic masses and pseudotumors</span><span class="headingEndMark"> — </span>Atypical manifestations of HSV-2 infection described in patients with HIV include hypertrophic masses, pseudotumors, nodular, or plaque-like lesions, which may be mistaken for squamous cell carcinoma of the vulva, scrotum, or other malignancies  (<a class="graphic graphic_picture graphicRef63362" href="/d/graphic/63362.html" rel="external">picture 2</a>) [<a href="#rid20">20,28,41-47</a>]. Hypertrophic lesions are often observed among patients with advanced immunodeficiency (eg, CD4 counts &lt;50 cells/mm<sup>3</sup>). This type of lesion can also be seen in a patient with a history of recurrent herpes and a low nadir CD4 cell count, despite ART-associated improvements in CD4 cell counts and HIV RNA suppression [<a href="#rid20">20,28,47</a>]. </p><p>Hypertrophic lesions may also be found in ectopic locations including the orofacial area or the endobronchial tree [<a href="#rid20">20,48,49</a>]. Genital HSV-2 lesions mimicking condyloma acuminata secondary to human papillomavirus infection have also been described  (<a class="graphic graphic_picture graphicRef75196" href="/d/graphic/75196.html" rel="external">picture 3</a>) [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H6231138"><span class="h2">Other unusual manifestations of HSV disease</span><span class="headingEndMark"> — </span>More serious clinical presentations of HSV reactivation include esophagitis, tracheitis, meningoencephalitis, hepatitis, pneumonitis, retinal necrosis, and disseminated disease, which are rare among HIV-seropositive patients [<a href="#rid51">51,52</a>]. However, herpetic lesions in atypical locations, such as the back, face or fingers (paronychia) [<a href="#rid39">39</a>] do occur and thus HSV should be considered in the differential of cutaneous lesions outside of the genital area. </p><p>Severe genital ulcers may occur in patients starting on antiretroviral therapy as part of the Immune Reconstitution Inflammatory Response (IRIS). The prevalence of IRIS and its implications for treatment of HIV and HSV are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/16255.html" rel="external">"Treatment of genital herpes simplex virus type 2 in people living with HIV", section on 'Immune reconstitution syndrome'</a>.)</p><p class="headingAnchor" id="H6231152"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A clinical diagnosis of genital herpes infection should be confirmed with diagnostic testing; this is particularly true in the individual with HIV where the clinical manifestations of disease may be altered. The diagnostic approach is similar to that in the HIV-seronegative patient [<a href="#rid25">25</a>]. Techniques include polymerase chain reaction (PCR), viral culture, and type-specific serologic tests. Occasionally, a biopsy may be required, as discussed below. </p><p class="headingAnchor" id="H11525273"><span class="h2">Ulcerative disease</span><span class="headingEndMark"> — </span>PCR-based testing is preferred for the diagnosis of HSV in a patient presenting with active lesions. Although both PCR and culture can determine the type of genital herpes (HSV-1 or HSV-2), PCR-based testing is much more sensitive than culture [<a href="#rid25">25</a>]. The diagnostic yield of either test is highest when the sample is taken from the base of a ruptured vesicle; the diagnostic yield declines rapidly as the lesion heals, especially for viral culture. Type-specific serologic testing to establish the presence of infection may be the preferred diagnostic test in patients with healing or small atypical lesions.</p><p>Details on the performance of these various tests are found elsewhere. (See  <a class="medical medical_review" href="/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H11525280"><span class="h2">Hypertrophic lesions</span><span class="headingEndMark"> — </span>A high index of suspicion for HSV-2 infection is needed in patients with pseudotumors or hypertrophic lesions (herpes vegetans), which can be mistaken for papillomatous lesions or other genital pathology. Surface samples of the lesion should be sent for PCR testing; if PCR testing is not available, a viral culture may be sent. If laboratory testing is not informative, the lesion should be biopsied for examination for viral inclusions [<a href="#rid28">28</a>]. Histologically, these tumors may be characterized by pseudoepitheliomatous hyperplasia, which may be difficult to differentiate from squamous cell carcinoma [<a href="#rid43">43,46,47</a>]. Dermatologic consultation is advised if the diagnosis is uncertain.</p><p class="headingAnchor" id="H12678014"><span class="h2">Patients with a recent history of genital disease</span><span class="headingEndMark"> — </span>Type-specific serologic testing may also be helpful in the patient with a history of recent genital ulcers who does not have any clinical findings on examination; antibodies to HSV-2 usually develop within 12 weeks after newly acquired infection [<a href="#rid53">53</a>]. Serologic testing performance varies by assay. Caution is suggested in interpreting low index value positive results, as false-positive tests can occur in both persons with and without HIV [<a href="#rid54">54</a>].</p><p>Routine serologic screening for HSV-2 in the asymptomatic patient is discussed below. (See <a class="local">'Screening for HSV-2 infection'</a> below.)</p><p class="headingAnchor" id="H11524576"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>HSV-2 is the leading cause of genital ulcer disease in both persons with [<a href="#rid55">55</a>] and without HIV [<a href="#rid1">1,56</a>]. The differential diagnosis of genital ulcerative disease, regardless of HIV status, includes other sexually transmitted diseases, such as syphilis and chancroid. </p><p>Painful ulcers tend to be more typical of HSV and chancroid, while ulcers associated with syphilis, lymphogranuloma venereum (LGV), and granuloma inguinale are usually painless. HSV-related ulcers are also usually recurrent by history. However, a clinical diagnosis made solely on these distinctions may be misleading, emphasizing the importance of laboratory testing. Noninfectious etiologies include fixed drug reactions, Behçet’s syndrome, neoplasms, and trauma. (See  <a class="medical medical_review" href="/d/html/7592.html" rel="external">"Approach to the patient with genital ulcers", section on 'General approach'</a>.)</p><p>Routine diagnostic evaluation of a patient with genital ulcers includes HSV PCR (preferred if available) or culture for HSV and a screening test for syphilis, such as a rapid plasma reagin (RPR). The decision to test for chancroid will be influenced by epidemiologic risk factors, such as travel to an endemic area. (See  <a class="medical medical_review" href="/d/html/7592.html" rel="external">"Approach to the patient with genital ulcers", section on 'General approach'</a>.)</p><p>In patients with atypical manifestations or hypertrophic lesions or masses, the differential diagnosis is broad and includes a variety of dermatologic disorders of the genital skin and mucosa, such as HPV infection. Malignancy must also be considered in the differential diagnosis, since cancer is an increasing cause of morbidity and mortality among patients with HIV in the era of potent ART [<a href="#rid57">57</a>]. If treatment of documented HSV infection does not lead to resolution, drug-resistant HSV or an alternative diagnosis must be considered [<a href="#rid58">58</a>]. Dermatologic consultation and a skin biopsy may be required. (See  <a class="medical medical_review" href="/d/html/8035.html" rel="external">"HIV infection and malignancy: Epidemiology and pathogenesis"</a>.)</p><p class="headingAnchor" id="H11524735"><span class="h1">SCREENING FOR HSV-2 INFECTION</span><span class="headingEndMark"> — </span>Many providers do not routinely screen their patients with HIV for herpes simplex 2 (HSV-2) infection, regardless of CD4 count, due to perceived lack of benefit, lack of time for counseling, and risk of anxiety related to the diagnosis. The United States Preventive Services Task Force (USPSTF) recommends against screening asymptomatic immunocompetent individuals for HSV-2 [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection", section on 'Screening'</a>.)</p><p>However, we typically screen persons with HIV infection and a CD4 count &lt;250 cells/microL for HSV-2 prior to initiating antiretroviral therapy (ART), even if they are asymptomatic. Testing should be performed using HSV type-specific serology. For those with evidence of HSV-2 infection, we administer suppressive antiviral therapy for HSV-2 (ie, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>) for three to six months after ART initiation to reduce the risk of developing HSV-2-related genital ulcer disease as a manifestation of an immune reconstitution inflammatory syndrome (IRIS) [<a href="#rid60">60-62</a>]. More detailed discussions of HSV-2-associated IRIS and suppressive antiviral therapy for HSV-2 are found elsewhere. (See  <a class="medical medical_review" href="/d/html/16255.html" rel="external">"Treatment of genital herpes simplex virus type 2 in people living with HIV", section on 'Immune reconstitution syndrome'</a> and  <a class="medical medical_review" href="/d/html/16255.html" rel="external">"Treatment of genital herpes simplex virus type 2 in people living with HIV", section on 'Suppressive therapy'</a>.) </p><p>HSV-2 serologic testing may also be reasonable for other patients as a way to inform counseling on how to reduce the risk of HSV-2 acquisition and transmission. As an example, condoms can reduce the risk of HSV transmission to an HSV-uninfected partner and may be particularly useful in preventing transmission from males with HSV-2 to females without HSV-2 [<a href="#rid61">61,63,64</a>]. By contrast, in patients with HIV who are not on ART, chronic suppressive antiviral therapy for HSV does not appear to prevent HSV-2 transmission to susceptible partners [<a href="#rid65">65</a>]. More detailed discussions of HSV-suppressive therapy in patients with HIV are found elsewhere. [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/16255.html" rel="external">"Treatment of genital herpes simplex virus type 2 in people living with HIV", section on 'Suppressive therapy'</a> and  <a class="medical medical_review" href="/d/html/8344.html" rel="external">"Prevention of genital herpes virus infections", section on 'Chronic suppressive therapy in discordant couples'</a>.)</p><p class="headingAnchor" id="H2974930377"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H6231095"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Herpes simplex virus type 2 (HSV-2) is the leading cause of genital ulcer disease (GUD) worldwide. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical designations of genital HSV infection are: primary, nonprimary first-episode, and recurrent or reactivation disease. Nonprimary first-episode infection refers to the acquisition of genital HSV-1 in a patient with preexisting antibodies to HSV-2 or the acquisition of genital HSV-2 in a patient with preexisting antibodies to HSV-1 (eg, an individual with prior orolabial herpes and an HSV-1 antibody response develops genital herpes due to acquisition of HSV-2 infection). Most adults with HIV and a first-episode HSV infection have nonprimary infection because of prior exposure to HSV-1. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiviral treatment during newly acquired infection lessens morbidity, but does not eradicate latent virus, which can subsequently reactivate in immunocompetent or immunocompromised hosts. (See <a class="local">'Reactivation disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiologic studies demonstrate that HSV-2 seroprevalence is disproportionately higher among persons with compared to those without HIV. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The natural history of HSV-2 infection is altered among patients with HIV infection. Among patients with HSV, concomitant HIV infection is associated with increased frequency and severity of genital ulcers. Advanced immunosuppression is associated with an increased risk of persistent non-healing ulcers and higher rates of subclinical viral shedding, which increases the risk of HSV-2 transmission. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations of HSV-2 infection vary according to the patient’s immunologic status. Genital ulcerations may range from unnoticed ulcers to typical herpetic lesions in the patient with well-controlled HIV infection to large, deep genital or perianal ulcerations in persons with advanced AIDS. Atypical presentations include pseudotumors or hypertrophic masses. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A clinical diagnosis of genital herpes infection should be confirmed with diagnostic laboratory testing; this is particularly true in individuals with HIV where the clinical manifestations of disease may be altered. The diagnostic approach is similar to that in patients without HIV. Techniques include: polymerase chain reaction (PCR), viral culture, and type-specific serologic tests. The choice of test will vary depending on the clinical presentation. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We typically screen patients with HIV and a CD4 count &lt;250 cells/microL for HSV-2 prior to initiating antiretroviral therapy (ART) for HIV, even if they are asymptomatic. For those who are HSV-2 seropositive and are initiating ART, we administer suppressive antiviral therapy for HSV-2 (ie, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>, <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>) to reduce the risk of developing an HSV-associated immune reconstitution inflammatory syndrome. HSV-2 serologic testing is also reasonable for other patients with HIV as a way to inform counseling on how to reduce the risk of HSV-2 acquisition and transmission. (See <a class="local">'Screening for HSV-2 infection'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mertz KJ, Trees D, Levine WC, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis 1998; 178:1795.</a></li><li><a class="nounderline abstract_t">Nilsen A, Kasubi MJ, Mohn SC, et al. Herpes simplex virus infection and genital ulcer disease among patients with sexually transmitted infections in Dar es Salaam, Tanzania. Acta Derm Venereol 2007; 87:355.</a></li><li><a class="nounderline abstract_t">Brankin AE, Tobian AA, Laeyendecker O, et al. Aetiology of genital ulcer disease in female partners of male participants in a circumcision trial in Uganda. Int J STD AIDS 2009; 20:650.</a></li><li><a class="nounderline abstract_t">Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243.</a></li><li><a class="nounderline abstract_t">Sanchez J, Volquez C, Totten PA, et al. The etiology and management of genital ulcers in the Dominican Republic and Peru. Sex Transm Dis 2002; 29:559.</a></li><li><a class="nounderline abstract_t">Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964.</a></li><li class="breakAll">http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/ (Accessed on January 06, 2012).</li><li><a class="nounderline abstract_t">Kouyoumjian SP, Heijnen M, Chaabna K, et al. Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence. AIDS 2018; 32:1343.</a></li><li><a class="nounderline abstract_t">Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006; 20:1051.</a></li><li><a class="nounderline abstract_t">Rabenau HF, Lennemann T, Kircher C, et al. Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho. Sex Transm Dis 2010; 37:454.</a></li><li><a class="nounderline abstract_t">Boulos R, Ruff AJ, Nahmias A, et al. Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type I infections. The Johns Hopkins University (JHU)/Centre pour le Developpement et la Santé (CDS) HIV Study Group. J Infect Dis 1992; 166:418.</a></li><li><a class="nounderline abstract_t">Romanowski B, Myziuk LN, Walmsley SL, et al. Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. Sex Transm Dis 2009; 36:165.</a></li><li><a class="nounderline abstract_t">Gwanzura L, McFarland W, Alexander D, et al. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J Infect Dis 1998; 177:481.</a></li><li><a class="nounderline abstract_t">Lama JR, Lucchetti A, Suarez L, et al. Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru. J Infect Dis 2006; 194:1459.</a></li><li><a class="nounderline abstract_t">Mbopi-Kéou FX, Grésenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090.</a></li><li><a class="nounderline abstract_t">Patel P, Bush T, Mayer KH, et al. Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. Sex Transm Dis 2012; 39:154.</a></li><li><a class="nounderline abstract_t">Bradley J, Floyd S, Piwowar-Manning E, et al. Sexually Transmitted Bedfellows: Exquisite Association Between HIV and Herpes Simplex Virus Type 2 in 21 Communities in Southern Africa in the HIV Prevention Trials Network 071 (PopART) Study. J Infect Dis 2018; 218:443.</a></li><li><a class="nounderline abstract_t">Schacker T. The role of HSV in the transmission and progression of HIV. Herpes 2001; 8:46.</a></li><li><a class="nounderline abstract_t">Bagdades EK, Pillay D, Squire SB, et al. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS 1992; 6:1317.</a></li><li><a class="nounderline abstract_t">Cury K, Valin N, Gozlan J, et al. Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient. Sex Transm Dis 2010; 37:126.</a></li><li><a class="nounderline abstract_t">Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med 1995; 123:845.</a></li><li><a class="nounderline abstract_t">DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.</a></li><li><a class="nounderline abstract_t">Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435.</a></li><li><a class="nounderline abstract_t">Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996; 156:1729.</a></li><li><a class="nounderline abstract_t">Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370:2127.</a></li><li><a class="nounderline abstract_t">Aumakhan B, Gaydos CA, Quinn TC, et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010; 5:e9973.</a></li><li><a class="nounderline abstract_t">Schacker T, Zeh J, Hu HL, et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616.</a></li><li><a class="nounderline abstract_t">Mosunjac M, Park J, Wang W, et al. Genital and perianal herpes simplex simulating neoplasia in patients with AIDS. AIDS Patient Care STDS 2009; 23:153.</a></li><li><a class="nounderline abstract_t">Posavad CM, Koelle DM, Shaughnessy MF, Corey L. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 1997; 94:10289.</a></li><li><a class="nounderline abstract_t">Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844.</a></li><li><a class="nounderline abstract_t">Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770.</a></li><li><a class="nounderline abstract_t">Mbopi Keou FX, Grésenguet G, Mayaud P, et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 1999; 13:536.</a></li><li><a class="nounderline abstract_t">Mostad SB, Kreiss JK, Ryncarz A, et al. Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. Am J Obstet Gynecol 2000; 183:948.</a></li><li><a class="nounderline abstract_t">Wright PW, Hoesley CJ, Squires KE, et al. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis 2003; 36:207.</a></li><li><a class="nounderline abstract_t">Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004; 190:693.</a></li><li><a class="nounderline abstract_t">Mayaud P, Nagot N, Konaté I, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect 2008; 84:332.</a></li><li><a class="nounderline abstract_t">Sandlin MI, Johnston C, Bowe D, et al. Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men. Sex Transm Dis 2011; 38:833.</a></li><li><a class="nounderline abstract_t">Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981; 305:1439.</a></li><li><a class="nounderline abstract_t">Mindel A, Carney O, Williams P. Cutaneous herpes simplex infections. Genitourin Med 1990; 66:14.</a></li><li><a class="nounderline abstract_t">1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.</a></li><li><a class="nounderline abstract_t">Yudin MH, Kaul R. Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy. Infect Dis Obstet Gynecol 2008; 2008:592532.</a></li><li><a class="nounderline abstract_t">Maharaj R, Parboosing R, Moodley M, et al. An unusual hypertrophic genital mass lesion--a diagnostic and treatment dilemma. J Clin Virol 2009; 46:303.</a></li><li><a class="nounderline abstract_t">Frimer M, Chudnoff S, Hebert T, Shahabi S. Pseudoepitheliomatous hyperplasia mimicking vulvar cancer in a patient with AIDS. J Low Genit Tract Dis 2011; 15:66.</a></li><li><a class="nounderline abstract_t">Boothby M, Radcliffe K. An unusual vulval lesion in an HIV-infected woman. Int J STD AIDS 2007; 18:218.</a></li><li><a class="nounderline abstract_t">Lautenschlager S, Schwarzkopf S, Keller B. Exophytic ulcerated tumors in HIV patients: diagnostic and therapeutic problems. Dermatology 2008; 216:60.</a></li><li><a class="nounderline abstract_t">Samaratunga H, Weedon D, Musgrave N, McCallum N. Atypical presentation of herpes simplex (chronic hypertrophic herpes) in a patient with HIV infection. Pathology 2001; 33:532.</a></li><li><a class="nounderline abstract_t">Ranu H, Lee J, Chio M, Sen P. Tumour-like presentations of anogenital herpes simplex in HIV-positive patients. Int J STD AIDS 2011; 22:181.</a></li><li><a class="nounderline abstract_t">Husak R, Tebbe B, Goerdt S, et al. Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient. Br J Dermatol 1998; 139:118.</a></li><li><a class="nounderline abstract_t">Plowman GM, Watson MW, D'Souza H, Thomas MG. Obstructive endo-bronchial pseudotumour due to herpes simplex type 2 infection in an HIV-infected man. Int J STD AIDS 2009; 20:737.</a></li><li><a class="nounderline abstract_t">Tong P, Mutasim DF. Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease. Br J Dermatol 1996; 134:797.</a></li><li><a class="nounderline abstract_t">Baras L, Farber CM, Van Vooren JP, Parent D. Herpes simplex virus tracheitis in a patient with the acquired immunodeficiency syndrome. Eur Respir J 1994; 7:2091.</a></li><li><a class="nounderline abstract_t">Lingappa JR, Celum C. Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection. Drugs 2007; 67:155.</a></li><li><a class="nounderline abstract_t">Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003; 30:310.</a></li><li><a class="nounderline abstract_t">Safrin S, Arvin A, Mills J, Ashley R. Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS. J Clin Microbiol 1992; 30:1312.</a></li><li><a class="nounderline abstract_t">Ahmed HJ, Mbwana J, Gunnarsson E, et al. Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities. Sex Transm Dis 2003; 30:114.</a></li><li><a class="nounderline abstract_t">Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect 2007; 83:16.</a></li><li><a class="nounderline abstract_t">Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011; 117:1089.</a></li><li><a class="nounderline abstract_t">Green T, Rogstad KE, Paterson ME. Genital herpes may mask underlying neoplasia. Sex Transm Infect 2001; 77:148.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2023; 329:502.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li class="breakAll">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Tobian AA, Grabowski MK, Serwadda D, et al. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis 2013; 208:839.</a></li><li><a class="nounderline abstract_t">Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143:707.</a></li><li><a class="nounderline abstract_t">Magaret AS, Mujugira A, Hughes JP, et al. Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples. Clin Infect Dis 2016; 62:456.</a></li><li><a class="nounderline abstract_t">Mujugira A, Magaret AS, Celum C, et al. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis 2013; 208:1366.</a></li><li><a class="nounderline abstract_t">Van Wagoner N, Geisler WM, Bachmann LH, Hook EW. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2. Int J STD AIDS 2015; 26:574.</a></li></ol></div><div id="topicVersionRevision">Topic 16254 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815237" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598041" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Herpes simplex virus infection and genital ulcer disease among patients with sexually transmitted infections in Dar es Salaam, Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710342" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aetiology of genital ulcer disease in female partners of male participants in a circumcision trial in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652447" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370522" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The etiology and management of genital ulcers in the Dominican Republic and Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926356" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16926356" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29794495" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16603858" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20531031" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1321862" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type I infections. The Johns Hopkins University (JHU)/Centre pour le Developpement et la Santé(CDS) HIV Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19098690" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466543" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054077" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979904" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22249305" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29659909" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sexually Transmitted Bedfellows: Exquisite Association Between HIV and Herpes Simplex Virus Type 2 in 21 Communities in Southern Africa in the HIV Prevention Trials Network 071 (PopART) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11867018" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The role of HSV in the transmission and progression of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361745" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858782" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bipolar hypertrophic herpes: an unusual presentation of acyclovir-resistant herpes simplex type 2 in a HIV-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486467" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10975963" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15021308" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694673" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156035" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Genital herpes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20376310" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815213" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19302018" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Genital and perianal herpes simplex simulating neoplasia in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294203" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727588" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7643884" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Virologic characteristics of subclinical and symptomatic genital herpes infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10197391" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035345" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522754" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15272395" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596069" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844739" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6272110" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2312113" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cutaneous herpes simplex infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361652" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784844" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786363" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An unusual hypertrophic genital mass lesion--a diagnostic and treatment dilemma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21192180" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pseudoepitheliomatous hyperplasia mimicking vulvar cancer in a patient with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17362560" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : An unusual vulval lesion in an HIV-infected woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032901" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Exophytic ulcerated tumors in HIV patients: diagnostic and therapeutic problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11827427" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Atypical presentation of herpes simplex (chronic hypertrophic herpes) in a patient with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21515747" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tumour-like presentations of anogenital herpes simplex in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9764162" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815922" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Obstructive endo-bronchial pseudotumour due to herpes simplex type 2 infection in an HIV-infected man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733396" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7875288" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Herpes simplex virus tracheitis in a patient with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284082" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12671550" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1316370" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12567167" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Etiology of genital ulcer disease and association with human immunodeficiency virus infection in two tanzanian cities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17098770" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Herpes simplex virus type 2: epidemiology and management options in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20960504" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11287706" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Genital herpes may mask underlying neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36786784" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Serologic Screening for Genital Herpes Infection: US Preventive Services Task Force Reaffirmation Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812240" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16287791" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The relationship between condom use and herpes simplex virus acquisition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26578538" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23901094" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25147236" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
